BASF sells pharma business to Abbott Labs for $6.9 billion in cash
Fooling most observers, Germany's BASF announced on December 15 that itis quitting the pharmaceutical business to concentrate on innovative chemistry, and is selling BASF Pharma, which includes the Knoll operations, to US drugmaker Abbott Laboratories for a consideration of $6.9 billion. The sell-off comes as no surprise, since it had been rumored for a month or so, but the speculation had focussed on the suitor being Eli Lilly.
The agreement, which has been approved by both companies' boards of directors, covers all German and international operations of BASF pharma and is subject to approval by regulatory agencies and customary closing conditions. Completion of the transaction, which is to be paid in cash, is scheduled for first-quarter 2001.
Fast growing profits in pharma business
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze